ClinicalTrials.gov
ClinicalTrials.gov Menu

Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Erectile Dysfunction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02344849
Recruitment Status : Unknown
Verified July 2016 by Pharmicell Co., Ltd..
Recruitment status was:  Active, not recruiting
First Posted : January 26, 2015
Last Update Posted : January 9, 2017
Sponsor:
Information provided by (Responsible Party):
Pharmicell Co., Ltd.

Brief Summary:
This phase I clinical trial is designed to evaluate the safety of autologous Mesenchymal Stem Cells (MSC) injected intracavernously.

Condition or disease Intervention/treatment Phase
Erectile Dysfunction Drug: mesenchymal stem cell (Cellgram-ED) Phase 1

Detailed Description:
Cellgram-ED is autologous bone marrow-derived mesenchymal stem cells ex vivo expanded for approximately 30 days. Ten patients (Diabetes -associated ED; 5 patients, Postprostatectomy; 5patients) will be injected Cellgram-ED directly into the intracavernous. Patient will be evaluated the safety and potential efficacy of MSC.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open, Single-center, Phase 1 Study to Evaluate Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cell in Erectile Dysfunction.
Study Start Date : July 2015
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : May 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Mesenchymal stem cell
Patients will receive single intracavernous injection of MSC. Oral PDE5-inhibitor can take on demand.
Drug: mesenchymal stem cell (Cellgram-ED)
Patients will receive single injection of Cellgram-ED( 30,000,000 MSC) intracavernously.
Other Name: Cellgram-ED




Primary Outcome Measures :
  1. Number and severity of adverse events [ Time Frame: 12month ]

Secondary Outcome Measures :
  1. Change From Baseline in the International Index of Erectile Function(IIEF) at 1, 3, 6, 9 and 12 month [ Time Frame: month 1, 3, 6, 9 and 12 ]
  2. Change From Baseline in Sexual Encounter Profile (SEP) Question 2, 3 at 1, 3, 6, 9 and 12 month [ Time Frame: month 1, 3, 6, 9 and 12 ]
  3. Global Assessment Question (GAQ) at 1, 3, 6, 9 and 12 month Endpoint [ Time Frame: month 1, 3, 6, 9 and 12 ]
  4. Change From Baseline in Peak systolic velocity (PSV) and End diastolic velocity (EDV) at 6 and 12 month [ Time Frame: month 6, 12 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Postprostatectomy Erectile Dysfunction

  • A man aged 20 or older
  • Who is willing to consent to participate in the study concerned with improving sexual activity after prostatectomy, the man has maintained normal sexual activity prior to prostatectomy
  • Prior to prostatectomy PSA (prostate specific antigen) level<10 ng/mL
  • At the time of Prostatectomy, Pathological Gleason sum ≤7
  • At the time of Prostatectomy, Pathological stage ≤ T2c
  • 2 years or more postprostatectomy patients with PSA level ≤ 0.04 ng/mL without additional therapy after prostatectomy
  • Who cannot satisfy sexual activity(more than 4 times) with proper sexual stimulation in spite of taking maximum dose of oral PDE5I(phos-phodiesterasetype-5 inhibitors) within last 8weeks.
  • IIEF, EF(erectile function) domain score is under 17
  • Have a consistent partner who is willing to engage in sexual activity more than twice per month during the study.

Diabetes-associated Erectile Dysfunction

  • HbA1c is between 6.5% and 10% of man over 20 years of age with diabetes
  • Who cannot satisfy sexual activity(more than 4 times) with proper sexual stimulation in spite of taking maximum dose of oral PDE5I within last 8weeks.
  • IIEF, EF domain score is under 17
  • Who is willing to consent to participate in the study concerned with improving sexual activity
  • Have a consistent partner who is willing to engage in sexual activity more than twice per month during the study.

Exclusion Criteria:

  • History of bone marrow disorders
  • Serum AST/ALT > 3 X upper limit of normal or Creatinine > 1.5 X upper limit of normal
  • History of hypersensitivity against a gentamycin
  • Severe cardiovascular disease(angina, arrhythmia, cardiac failure, stroke), kidney failure, respiratory failure
  • Positive for human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and syphilis test
  • Positive for PSA or CEA or AFP (Carcinoembryonic antigen), history of cancer in the last five years (except Prostatic cancer) Uncontrolled hypertension or hypotension (systolic blood pressure > 170 or < 90 mm Hg, diastolic pressure > 100 or < 50 mm Hg)
  • HbA1c exhibit greater than 10%
  • Men on anticoagulant treatment
  • Have a severe infectious disease
  • Testosterone level is less than 200ng/dl
  • Have a penile implant or willing to it
  • Patients with morphological changes of the penis
  • Patient's partner is trying to conceive during the trial period
  • Unwilling to participate in the study
  • Participating in other clinical trials in the past 30 days
  • Unable to compliance with protocol
  • Inappropriate patients to participate in the study according to the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02344849


Locations
Korea, Republic of
Asan medical center
Songpagu, Seoul, Korea, Republic of
Sponsors and Collaborators
Pharmicell Co., Ltd.
Investigators
Principal Investigator: Chungsu Kim, Ph.D AIDS Malignancy Consortium

Responsible Party: Pharmicell Co., Ltd.
ClinicalTrials.gov Identifier: NCT02344849     History of Changes
Other Study ID Numbers: Cellgram-ED
First Posted: January 26, 2015    Key Record Dates
Last Update Posted: January 9, 2017
Last Verified: July 2016

Additional relevant MeSH terms:
Erectile Dysfunction
Sexual Dysfunction, Physiological
Genital Diseases, Male
Sexual Dysfunctions, Psychological
Mental Disorders